Nicholas J. Silvestri

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Regional variation of Guillain-Barré syndrome

Alex Y. Doets, Christine Verboon, Bianca van den Berg et al. · Brain · 2018 · 330 citations · Full text

Medicine, Internal Medicine, Neurology +16

Rituximab as treatment for anti-MuSK myasthenia gravis

Michael K. Hehir, Lisa D. Hobson‐Webb, Michael Benatar et al. · Neurology · 2017 · 248 citations

Pharmacy, Immunology, Pharmacotherapy +15

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial

Gil I. Wolfe, Henry J. Kaminski, Inmaculada Aban et al. · The Lancet Neurology · 2019 · 223 citations · Full text

Medicine, Endocrinology, Surgery +5

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis

James F. Howard, Richard J. Nowak, Gil I. Wolfe et al. · JAMA Neurology · 2020 · 193 citations · Full text

Life Sciences, Immunology, Pharmacology +17